Heart Test Laboratories Inc (HSCS)

$3.24 -0.13 (-3.86%)
Market Cap 2.27M
Revenue (ttm) 20,000.00
Net Income (ttm) -6.61M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 11,938
Avg Vol 455,542
Day's Range N/A - N/A
Shares Out 656,000.00
Stochastic %K 24%
Beta 3.16
Analysts Strong Sell
Price Target $13.50

Company Profile

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventi...

Industry: Medical Devices
Sector: Healthcare
Phone: 682 237 7781
Address:
550 Reserve Street, Suite 360, Southlake, United States
DrTampa
DrTampa Oct. 3 at 4:15 AM
$HSCS Still here, my position is now nearly 147,000 shares. Happy staying under 5%. LFG FDA submission and some meaningful revenue from Myovista Insights!!!
1 · Reply
DARKP00L
DARKP00L Oct. 1 at 10:58 AM
$HSCS 06:27 on Oct. 01 2025 Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $9 #tradeideas
1 · Reply
Moneyybaggs
Moneyybaggs Sep. 25 at 3:38 PM
$HSCS I sense she’s about to blow!!!
1 · Reply
Moneyybaggs
Moneyybaggs Sep. 25 at 1:47 PM
$HSCS Are hospitals/cardiologists utilizing the myovista insight cloud platform? Are they paying to use the algos hosted in the cloud?!? That’s the $10M question!
0 · Reply
LuisBaldwin295
LuisBaldwin295 Sep. 22 at 7:36 AM
$HSCS Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum.
0 · Reply
Moneyybaggs
Moneyybaggs Sep. 19 at 6:00 AM
$HSCS You are 1000% correct @14745Barclay! Simpson and the management team have lost all credibility with investors. They have proven to be exceptionally adept at capital destruction. The 1 for 100 reverse split resoundingly supports that fact. It has become a SHOW ME stock where no investor takes a position on potential. Simpson missing about a dozen deadlines for FDA submission has only added to investor misery. The potential returns are mesmerizing but potential must lead to execution and that is where Simpson and his crew have fallen woefully short and been severely lacking. However, I still believe Simpson gets this technology across the finish line and begins to generate revenue. Still hopeful and
1 · Reply
14745Barclay
14745Barclay Sep. 18 at 2:06 PM
$HSCS At this point, nothing, I mean no meaningful news is going to matter. Even if they announce FDA submission completes, the stock will probably bounce initially and then sell off intensely. Investors have zero confidence in the management’s capability to anything done.
1 · Reply
DrTampa
DrTampa Sep. 18 at 4:51 AM
$HSCS Yasss zadddyyyyy
0 · Reply
DrTampa
DrTampa Sep. 17 at 11:36 PM
$HSCS $HEARTSCIENCES Inc Don't forget who told you before it made official news 🤑🤑🫡 I beat the filing by about 12 hours!
0 · Reply
dbr_island
dbr_island Sep. 17 at 9:59 PM
CAPS been loading ALL day for a reason WATCH AND LEARN LIKE $ATCH $NVOX $HSCS $ERNA
0 · Reply
Latest News on HSCS
HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

Sep 11, 2025, 4:15 PM EDT - 23 days ago

HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

HeartSciences Announces Conference Participation and Investor Webinar

Aug 15, 2025, 9:00 AM EDT - 7 weeks ago

HeartSciences Announces Conference Participation and Investor Webinar

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

Jul 24, 2025, 4:15 PM EDT - 2 months ago

HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Jun 4, 2025, 9:00 AM EDT - 4 months ago

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

Jun 3, 2025, 9:00 AM EDT - 4 months ago

Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

May 29, 2025, 9:00 AM EDT - 4 months ago

HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

May 20, 2025, 9:00 AM EDT - 4 months ago

HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

May 8, 2025, 9:00 AM EDT - 5 months ago

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

May 7, 2025, 9:00 AM EDT - 5 months ago

HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

May 1, 2025, 9:00 AM EDT - 5 months ago

HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 4:15 PM EDT - 7 months ago

HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

Mar 10, 2025, 9:00 AM EDT - 7 months ago

HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

Dec 16, 2024, 4:15 PM EST - 10 months ago

HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

Nov 13, 2024, 9:00 AM EST - 11 months ago

HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

Sep 12, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

Sep 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 1 year ago

HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

Jul 26, 2024, 9:00 AM EDT - 1 year ago

Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

Jul 25, 2024, 8:30 AM EDT - 1 year ago

HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Jul 11, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

HeartSciences Regains Compliance with Nasdaq Listing Requirements

Jun 4, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Regains Compliance with Nasdaq Listing Requirements

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

May 20, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

Apr 24, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences to Present at the LD Micro Invitational XIV Conference

Apr 2, 2024, 4:15 PM EDT - 1 year ago

HeartSciences to Present at the LD Micro Invitational XIV Conference

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Mar 26, 2024, 9:00 AM EDT - 1 year ago

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

Mar 14, 2024, 4:15 PM EDT - 1 year ago

HeartSciences Reports Third Quarter Fiscal 2024 Financial Results

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

Mar 12, 2024, 9:00 AM EDT - 1 year ago

HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

Mar 6, 2024, 9:00 AM EST - 1 year ago

HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Feb 26, 2024, 9:00 AM EST - 1 year ago

HeartSciences Adds Key Advisor to its Scientific Advisory Board

HeartSciences Expands its Scientific Advisory Board

Feb 12, 2024, 9:00 AM EST - 1 year ago

HeartSciences Expands its Scientific Advisory Board

HeartSciences Appoints New Scientific Advisory Board Member

Feb 1, 2024, 9:00 AM EST - 1 year ago

HeartSciences Appoints New Scientific Advisory Board Member

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

Jan 18, 2024, 8:00 AM EST - 1 year ago

HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

Jan 3, 2024, 4:15 PM EST - 1 year ago

HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:15 PM EST - 1 year ago

HeartSciences Reports Second Quarter Fiscal 2024 Financial Results

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

Dec 5, 2023, 8:00 AM EST - 1 year ago

HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Nov 13, 2023, 8:45 AM EST - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

Nov 3, 2023, 8:28 AM EDT - 2 years ago

Top 5 Health Care Stocks That Are Preparing To Pump In November - Better Therapeutics (NASDAQ:BTTX), Arcutis Biotherapeutics (NASDAQ:ARQT)

ARQT SINT

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

Sep 14, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Reports First Quarter Fiscal 2024 Financial Results

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

Sep 12, 2023, 4:15 PM EDT - 2 years ago

HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

Sep 11, 2023, 4:15 PM EDT - 2 years ago

HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

Sep 7, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

Aug 31, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Signs Distribution Agreement with FJ Medical, Denmark

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

Aug 24, 2023, 9:00 AM EDT - 2 years ago

HeartSciences' MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

Aug 17, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

Jul 27, 2023, 9:00 AM EDT - 2 years ago

MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

Jul 19, 2023, 9:00 AM EDT - 2 years ago

HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

May 17, 2023, 8:00 AM EDT - 2 years ago

HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

May 9, 2023, 8:15 AM EDT - 2 years ago

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

May 8, 2023, 8:15 AM EDT - 2 years ago

HeartSciences to Participate at the Inaugural EF Hutton Global Conference

DrTampa
DrTampa Oct. 3 at 4:15 AM
$HSCS Still here, my position is now nearly 147,000 shares. Happy staying under 5%. LFG FDA submission and some meaningful revenue from Myovista Insights!!!
1 · Reply
DARKP00L
DARKP00L Oct. 1 at 10:58 AM
$HSCS 06:27 on Oct. 01 2025 Ascendiant Capital Maintains Buy on HeartSciences, Lowers Price Target to $9 #tradeideas
1 · Reply
Moneyybaggs
Moneyybaggs Sep. 25 at 3:38 PM
$HSCS I sense she’s about to blow!!!
1 · Reply
Moneyybaggs
Moneyybaggs Sep. 25 at 1:47 PM
$HSCS Are hospitals/cardiologists utilizing the myovista insight cloud platform? Are they paying to use the algos hosted in the cloud?!? That’s the $10M question!
0 · Reply
LuisBaldwin295
LuisBaldwin295 Sep. 22 at 7:36 AM
$HSCS Healthcare technology growth. Testing resistance level. Volume confirmation needed. Sector momentum.
0 · Reply
Moneyybaggs
Moneyybaggs Sep. 19 at 6:00 AM
$HSCS You are 1000% correct @14745Barclay! Simpson and the management team have lost all credibility with investors. They have proven to be exceptionally adept at capital destruction. The 1 for 100 reverse split resoundingly supports that fact. It has become a SHOW ME stock where no investor takes a position on potential. Simpson missing about a dozen deadlines for FDA submission has only added to investor misery. The potential returns are mesmerizing but potential must lead to execution and that is where Simpson and his crew have fallen woefully short and been severely lacking. However, I still believe Simpson gets this technology across the finish line and begins to generate revenue. Still hopeful and
1 · Reply
14745Barclay
14745Barclay Sep. 18 at 2:06 PM
$HSCS At this point, nothing, I mean no meaningful news is going to matter. Even if they announce FDA submission completes, the stock will probably bounce initially and then sell off intensely. Investors have zero confidence in the management’s capability to anything done.
1 · Reply
DrTampa
DrTampa Sep. 18 at 4:51 AM
$HSCS Yasss zadddyyyyy
0 · Reply
DrTampa
DrTampa Sep. 17 at 11:36 PM
$HSCS $HEARTSCIENCES Inc Don't forget who told you before it made official news 🤑🤑🫡 I beat the filing by about 12 hours!
0 · Reply
dbr_island
dbr_island Sep. 17 at 9:59 PM
CAPS been loading ALL day for a reason WATCH AND LEARN LIKE $ATCH $NVOX $HSCS $ERNA
0 · Reply
DrTampa
DrTampa Sep. 17 at 7:36 AM
$HSCS Looks like we have been removed from the Nasdaq Non Compliant list :) :) :) https://www.nasdaq.com/market-activity/stocks/non-compliant-company-list?page=1&rows_per_page=100
0 · Reply
martins1
martins1 Sep. 16 at 4:11 PM
$HSCS beautiful set up
0 · Reply
cleggatt
cleggatt Sep. 16 at 1:53 PM
$HSCS is the C-Suite is like trying to avoid the perp-walk of shames by becoming a sequel to Theranos & Ms. Holmes? Often, to good to be true is exactly that.
0 · Reply
DrTampa
DrTampa Sep. 16 at 8:15 AM
$HSCS I love when my buy orders are filled but don't show up on the tick by tick or in the days cumulative volume. See other pictures below:
2 · Reply
DrTampa
DrTampa Sep. 15 at 4:22 AM
$HSCS sooo I haven't spoke to Andrew in well over a year, but I talk to Mark in IR every week or two. I have said multiple times they need to get device FDA submission done even if the algo is done seperately. I'm very glad to see this is the new plan! Get device submission done, and do the algo once it has been updated according to July guidance for the expanded data set. Veryyyyyyyyy bullish on this one RN since FDA submission could come any day if the device is truly ready!
1 · Reply
Moneyybaggs
Moneyybaggs Sep. 12 at 5:39 PM
$HSCS When is Simpson going to FINALLY deliver the FDA submission?!? He’s moved the goal posts at least a dozen times. So much supposed potential but Andrew Simpson can’t seem to get out of the way of his own shadow!!! No one is buying that offering at $3.50 when the stock is at $3.00 even if a warrant is attached. I own 58K shares unfortunately at $4.67 per share. Would love to average down but have absolutely no confidence in Simpson to deliver. Especially when this elusive FDA submission has been delayed at least 18 months. LFGOOOOOOOOOO Simpson!!!
0 · Reply
14745Barclay
14745Barclay Sep. 12 at 1:41 PM
$HSCS This might be heading towards sub 3 as investors have almost zero confidence in management’s ability to execute. They can‘t even get the FDA submission in while competitors have already received their algorithm approvals in 2024.
0 · Reply
99DegreesInvestments
99DegreesInvestments Sep. 11 at 10:06 PM
$HSCS hello
1 · Reply
BearishAlgo
BearishAlgo Sep. 11 at 9:55 PM
$HSCS
0 · Reply
YungnredE
YungnredE Sep. 11 at 8:21 PM
$HSCS I want to believe in this... and can't believe I'm actually saying this but if it's not from China this week, I don't trust it 🫥
0 · Reply
BearishAlgo
BearishAlgo Sep. 11 at 8:18 PM
$HSCS: (USA, EARNINGS) Critical Zone $3.75 - $3.95 📈 Plan A: Watch for a breakout & hold for a support flip. 📉 Plan B: Watch for rejection.
0 · Reply
BigSqueezeComing
BigSqueezeComing Sep. 11 at 8:17 PM
$HSCS 2 M float
0 · Reply